



The art of partnerships

Program Agenda

Developing Countries Vaccine Manufacturers' Network
19th Annual General Meeting
29th October - 1st November 2018
Kunming, China

DAY 1 - Monday, October 29th - Pre-meetings

08:30 - 10:00	Registrations - Welcome coffee	8:30 – 11:00 / Danxia Room DCVMN Executive Committee Meeting 11:00 - 12:30 / Danxia Room DCVMN Executive Committee Meeting with BMGF Private meeting for Executive Committee members: by Invitation Only
10:00 - 12:30	Satellite Workshop for DCVMN corporate members only: Responsible Innovation and the Future Vaccine Manufacturing Hub - Hosted by The Future Vaccine Hub / Chambord room Chair: <i>R. Shattock</i> (Leader FVMH) Co-chair: <i>K. Kothari</i> (FVMH)	
10:00 - 10:15	Introduction to the Future Vaccine Manufacturing Hub. <i>R. Shattock/K. Kothari</i>	Time for Networking and private meetings
10:15 - 10:30	Replicon RNA vaccines. <i>R. Shattock</i>	
10:30 - 10:50	Enhanced yeast expression platforms QA & Insect-cell baculovirus expression system (IC-BEVS). <i>X. Xu</i> (Imperial College London)	
10:50 - 11:10	Insect-cell baculovirus expression system (IC-BEVS). <i>I. Berger</i> (University of Bristol)	
11:10 - 11:30	Process optimisation, formulation, and heat stabilization. <i>R. Chen</i> (Imperial College London)	
11:30 - 11:50	QA and QC support. <i>M. Page</i> (NIBSC)	
11:50 - 12:10	Vaccine specific modelling and decisional tools. <i>Z. Kis</i> (Imperial College London)	
12:10 - 12:20	Using synthetic biology to develop oral, thermostable vaccines. <i>T. Fjaellman</i> (Prokarium)	
12:20- 12:30	Q&A	
12:30 - 14:00	Lunch for DCVMN corporate members only	
14:00 - 16:00	Satellite Symposium For ALL PARTICIPANTS – Chambord room Responsible Innovation: Cost-effective manufacturing and economies of scale – Hosted by DCVMN Premium Partners Chair: <i>CB. Tan</i> (Merck) Co-chair: <i>T. Prusik</i> (Temptime). Rapporteur: <i>S. Pagliusi</i> (DCVMN)	
14:00 - 14:20	Adapting VVM for the Next Generation Supply Chain. <i>T. Prusik</i> (Temptime)	Time for Networking and private meetings
14:20 - 14:40	Accelerating vaccine process development through collaborations. <i>R. Patil</i> (Merck)	
14:40 - 15:00	Adenovirus based vaccine manufacturing - technical and economic considerations. <i>M. Lundgren</i> (GE)	
15:00 - 15:20	Vaccine Packaging with Blow/Fill/Seal technology: devices, vaccine compatibility and economic considerations. <i>T. Kram</i> (Rommelag)	
15:20 - 15:40	DCVMN partnerships portal <i>P. Houry</i> (Ology Bioservices)	
15:40 - 16:00	Coffee break	
16:00 - 18:00	DCVMN General Assembly: for DCVMN corporate members only	Time for Networking and private meetings
18:00 - 19:30	Welcome Reception / For all participants / Foyer area	

DAY 2 – Tuesday, October 30th

08:30 - 09:00	Registrations		
09:00 - 10:00	Plenary Opening Session / Grand Ballroom Rapporteur: <i>J. Li</i> (IMBCAMS)		
09:00 - 10:00	Chair: <i>M. Datla</i> , (President, DCVMN) Co-chair: <i>L. Qihan</i> , (CEO & President, IMBCAMS) Rapporteur: <i>J. Li</i> (IMBCAMS)	Opening Address <i>M. Datla</i> (President, DCVMN)	
		Welcome Speech by <i>L. Qihan</i> (CEO & President, IMBCAMS)	
		Inaugural Address Ministry of Health and Welfare China/Yunnan	
		Inaugural Speech: WHO new strategic directions <i>M. Simao</i> (Assistant Director General for Access, WHO)	
10:00 - 10:30	Coffee Break		
10:30 - 11:30	Partnerships for Vaccines' Forum / Grand Ballroom Chair: <i>L. Yang</i> (Sinopharm) Co-chair: <i>H. Kim</i> (SK). Rapporteur: <i>S. Xie</i> (CHAI)		
10:30 - 11:30	Inaugural keynote lectures	Partnerships for the next decade in Global Health. <i>A. Oswald</i> (BMGF)	
		PATH 40 years of transformational innovations <i>S. Davis</i> (PATH)	
		Partnerships, competition and strategic procurement. <i>E. Kadilli</i> (UNICEF)	
11:30 - 12:30	Panel discussion I moderated by <i>J. Chu</i> (CHAI)	Vaccine innovation through partnerships <i>S. Davis</i> (PATH), <i>H. Iyer</i> (BMGF), <i>M. Simao</i> (WHO), <i>M. Zuma</i> (Bio-Manguinhos), <i>P. Tippoo</i> (Biovac)	
12:30 - 14:00	Lunch		
14:00 - 17:30	Procurement, Financing, and Innovation Forum / Grand Ballroom Rapporteur: <i>J. Li</i> (IMBCAMS) / <i>S. Xie</i> (CHAI)		
14:00 - 15:00	Panel discussion II moderated by <i>V. Pavliak</i> (IVI)	Vaccines R&D <i>D. Robinson</i> (BMGF), <i>R. Shattock</i> (Imperial), <i>DT. Do</i> (Vabiotech), <i>A. Tomar</i> (Cadila), <i>R. Suri</i> (Panacea Biotec), <i>S. Dong</i> (IMBCAMS)	
15:00 - 16:00	Panel discussion III moderated by <i>E. Baker</i> (GAVI)	Innovative Procurement and Globalization for vaccines Introduction by <i>T. Cernuschi</i> (WHO), <i>D. Hein</i> (GAVI), <i>J. Fitzsimmons</i> (PAHO), <i>A. Ottosen</i> (UNICEF), <i>R. Iqbal</i> (BMGF)	
16:00 - 16:30	Coffee Break		
16:30 - 17:30	Panel discussion IV moderated by <i>G. Rockman</i> (GHIF)	Funding Landscape: New prospects for investing in Vaccines <i>F. Kristensen</i> (CEPI), <i>M. Datla</i> (BioE), <i>S. Prasad</i> (Bharat), <i>J. Yip</i> (BMGF)	
17:30 - 18:30	Free Time for Networking	DCVMN Elections – members only event	Bill & Melinda Gates Foundation: Open House (cocktail served) / Cuiyu room
19:00 - 21:00	Cultural Dinner / Pavilion sponsored by IMBCAMS for all participants		

DAY 3 – Wednesday, October 31st

08:00 - 09:00	Informal breakfast for the EC	
09:00 - 10:30	Regulatory Forum: increasing regulatory convergence / Grand Ballroom A Chair: <i>N. Dellepiane</i> (DCVMN consultant) Co-chair: <i>S. Desai</i> (Zydus Cadila) Rapporteur: <i>S. Pagliusi</i> (DCVMN)	Future Vaccines Forum / Grand Ballroom B Chair: <i>S. Jadhav</i> (Serum Institute of India) Co-chair: <i>S. Khomvilai</i> (QSMI) Rapporteur: <i>J. Li</i> (IMBCAMS)
09:00 - 10:30 (15 minutes each)	The collaborative procedure for advancing vaccines' registration in emerging countries <i>E. Cooke</i> (WHO) CFDA representative (tbc) Joint scientific and ethics reviews of clinical trial applications <i>D. Maiga</i> (AVAREF) Opportunities for improvements in vaccines registration <i>N. Dellepiane</i> (DCVMN consultant) Collaborative evaluation of marketing authorization files of IPV in countries of the EMR (video), <i>H. Langar</i> (WHO EMRO)	Accelerating vaccine discovery and development. <i>D. Robinson</i> (BMGF) Experience with the first wP based fully liquid hexavalent vaccine <i>R. K. Suri</i> (Panacea) New 5-valent meningitis vaccine <i>R. Dhere</i> (Serum Institute of India) PCV-13 clinical results. <i>S. Yang</i> (Walvax) Development of shigella vaccine <i>L. Du</i> (Zhifei) Phase I and II trials of a F genotype live attenuated mumps vaccine <i>Y. Che</i> (IMBCAMS) Q&A
10:30 - 11:00	Coffee Break	
11:00 - 12:30 (15 minutes each)	Future QC assays and standards Forum: QC Tech transfer to DCVMs / Grand Ballroom A Chair: <i>I. Feavers</i> (NIBSC) Co-chair: <i>H.S. Kim</i> (LG) Rapporteur: <i>W. Bakker</i> (Intravacc)	Future vaccines Forum / Grand Ballroom B - part 2 Chair: <i>A. Wong</i> (Walvax) Co-chair: <i>R. Shattock</i> (Imperial College London) Rapporteur: <i>J. Li</i> (IMBCAMS)
	WHO Global NCLs Network <i>U. Roskopf</i> (WHO) Global efforts to improve vaccine testing. <i>I. Feavers</i> (NIBSC) Availability of high quality, affordable, and accessible monoclonal antibodies to support PCV development <i>D. Boyle and N. Agarwal</i> (PATH) QC testing of bacterial vaccines: D, T, P. <i>G. Kersten</i> (Intravacc) Establishment of international reference for sabin IPV. <i>S. Boyle and K. Mahmood</i> (BMGF/PATH)	Second generation rotavirus vaccines <i>C. Kirkwood</i> (BMGF) Rabies monoclonal product <i>S. Kumar</i> (Zydus Cadila) Novel vaccines against mosquito born viruses. <i>S. Misailidis</i> (Biomanguinhos) Clinical development of sabin IPV <i>W. Meng</i> (Sinovac) Advancements in novel manufacturing: HPV & HEV <i>J. Shih</i> (Innovax) Dengue, second generation vaccines <i>A. Precioso</i> (Butantan)
12:30 - 14:00	Lunch	
14:00 - 15:30	Novel strategies to improve vaccine coverage and equity/ Grand Ballroom Chair: <i>B. Giersing</i> (WHO) Co-chair: <i>S. Gao</i> (Innovax) Rapporteur: <i>B. Kanduri</i> (PATH)	Updates on progress of UNICEF / Grand Ballroom Chair: <i>E. Kadilli</i> (UNICEF) Co-chair: <i>Y. Momeni</i> (UNICEF) Rapporteur: tbc
14:00 - 15:30	Innovative technologies: TSE, VIPS, MAP, CTC. <i>B. Giersing</i> (WHO) Panel discussion V moderated by <i>D. Kristensen</i> (PATH), <i>R. Kapoor</i> (National University of Singapore), <i>V. Hsu</i> (BMGF), <i>D. Hein</i> (GAVI), <i>Y. Baik</i> (EuBiologics), <i>S. Jadhav</i> (SII)	Panel discussion VI moderated by <i>E. Kadilli</i> (UNICEF), <i>Y. Momeni</i> (UNICEF), <i>T. Cernuschi</i> (WHO), <i>R. Iqbal</i> (BMGF), <i>N. Steensma</i> (CHAI), <i>R. Suri</i> (Panacea Biotech), <i>S. Li</i> (Walvax)
15:30 - 16:00	Coffee Break	
16:00 - 17:00	Plenary Closing Session / Grand Ballroom	

	Rapporteur: <i>S. Pagliusi</i> (DCVMN)	
16:00 - 17:00	Chair:	Closing Keynote Lecture: Influenza vaccine supply hubs. <i>C. Nannei</i> (WHO)
	<i>A. Precioso</i> (Vice President, DCVMN)	Closing Remarks



中國醫藥科學院醫學生物學研究所
INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

Day 4 - Thursday, November 1st

Optional site visits to IMBCAMS facilities

08:30	Bus pick up from the venue
09:20	Arrival at IMBCAMS facilities
09:30 - 11:30	Visit
11:30	End of the visit / lunch at IMBCAMS facilities
14:00	Back at the venue

